Xeris is an Austin-based pharmaceutical company dedicated to the development of patient-friendly injectable drugs to address important unmet medical needs while improving patient compliance, lowering total costs of treatment, and having a positive impact on patient and caregiver quality of life.

from http://www.xerispharma.com/#!company/aboutPage

Research Grants show all

NIH14

Publications show all

Xeris Pharmaceuticals has published 4 articles.

Patents show all

Xeris Pharmaceuticals has 1 licensable patents.
43Applications28Issued

Clinical Trials show all

8Phase 22Phase 31Phase 1/Phase 2

SEC Filings show all

D8

SEC Form D Funding Events

DateOfferedSoldType
2014-09-29$14,874,990$7,274,592Equity
2013-07-10$3,000,000$2,315,000Debt, Security to be Acquired
2013-02-14$3,000,000$1,750,000Debt, Security to be Acquired
2012-09-25$3,000,000$1,125,000Debt, Security to be Acquired
2011-10-12$1,958,748$1,837,848Equity, Option to Acquire, Security to be Acquired
2005-11-29UnknownUnknownOther (Paper Filing)

Key Executives

  • Yash Sabharwal
    Executive Officer
  • John Kinzel
    Executive Officer, Director
  • Doug Baum
    Director
  • Steven Prestrelski
    Executive Officer, Director
  • John Kinzell
    Executive Officer, Director
  • Douglas Baum
    Director
  • Timothy Sullivan
    Director
  • Shane Brisbin
    Director